Sign up
Pharma Capital

Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln.

The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a upfront sum of US$3.5mln.

 

View full REDX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.